Senior Director, New Ventures (Canada) and Advisor, Impact Investing, J&J Global Community Impact
Jennifer Hamilton has scouted, cross-sector, for new opportunities for Johnson & Johnson in Canada since 2010 – first with the Corporate Office of Science and Technology (COSAT) and now with J&J Innovation. As well, Jennifer serves as the industry representative on the Canadian Institutes of Health Research (CIHR, Canadian equivalent of NIH) Standing Committee on Ethics. Since 2017, Jennifer has additionally worked with the J&J Global Community Impact team on a new initiative to test Impact Investing in global health where she is seeking healthcare investments worldwide that have social impact and financial return enabling scaling of technology and services in ultra-low resource settings.
Prior to working with J&J, Jennifer spent 17 years in biotech venture capital as Venture Partner at UK-based Nomura Phase4 Ventures and an Investment Director with Rothschild Asset Management covering North American and Canada respectively. She has also been an advisor to early and late-stage companies, venture funds and pension funds giving financing, business development and M&A advice. Jennifer has an MSc and a PhD in Experimental Pathology/Lipid Metabolism from the University of British Columbia and a BSc from the University of Guelph.